I'm not trying to interrupt the narrative here, but are clinical study results for NNZ-2591 that impressive? The market is probably suggesting that the drug isn't that effective and is at risk of regulatory denial. Therefore the SP reflects anxiety about plateauing sales of Daybue and delayed rollout to ROW.
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-11153
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.94 |
Change
-0.290(1.79%) |
Mkt cap ! $2.037B |
Open | High | Low | Value | Volume |
$16.33 | $16.37 | $15.78 | $10.73M | 671.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | $15.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$16.02 | 1422 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | 15.900 |
1 | 3286 | 15.870 |
3 | 3218 | 15.850 |
1 | 1357 | 15.840 |
2 | 2146 | 15.820 |
Price($) | Vol. | No. |
---|---|---|
16.020 | 1422 | 2 |
16.040 | 1796 | 1 |
16.070 | 1796 | 1 |
16.090 | 2700 | 1 |
16.100 | 1796 | 1 |
Last trade - 16.10pm 13/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online